Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.58 |
| ▸ | BCHE | P06276 | 8/20 | 0.57 |
| ▸ | BACE1 | P56817 | 8/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42501 | 1.00 | ACHE (0.58) | ACHEBCHEBACE1LTA4HCCR3 | |
| SCHEMBL330609 | 1.00 | ACHE (0.58) | ACHEBCHEBACE1LTA4HCCR3 | |
| SCHEMBL14793661 | 1.00 | ACHE (0.58) | ACHEBCHEBACE1LTA4HCCR3 | |
| Bromide SCHEMBL2495449 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Hydrochloric Acid SCHEMBL697482 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Hydrochloric Acid SCHEMBL2905438 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Hydrochloric Acid SCHEMBL20183286 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Bromide SCHEMBL2899465 | 0.98 | ACHE (0.56) | ACHEBCHEBACE1LTA4HCCR3 | |
| Acetic Acid SCHEMBL2500600 | 0.91 | ACHE (0.53) | ACHELTA4HALDH1A1SIGMAR1DRD2 | |
| Acetic Acid SCHEMBL2904677 | 0.91 | ACHE (0.53) | ACHELTA4HALDH1A1SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111718250-B | Method for preparing R-citronellal | 万华化学集团股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-111718250-A | Method for preparing R-citronellal | 万华化学集团股份有限公司 | 2020-09-29 | — | — | CN | claimed |
| CN-111620802-A | Preparation method of cefditoren intermediate (R) -1-benzyl-3-aminopyrrolidine | 山西千岫制药有限公司 | 2020-09-04 | — | — | CN | claimed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | claimed |
| CN-102603592-B | Preparation method for (R)-1-benzyl-3-aminopyrrolidine and (S)-1-benzyl-3-aminopyrrolidine | SHANGHAI INST TECHNOLOGY | 2014-08-20 | — | — | CN | claimed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | claimed |
| CN-102603592-A | Preparation method for (R)-1-benzyl-3-aminopyrrolidine and (S)-1-benzyl-3-aminopyrrolidine | SHANGHAI INST TECHNOLOGY | 2012-07-25 | — | — | CN | claimed |
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |
| US-7417152-B2 | 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2008-08-26 | — | — | US | claimed |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| EP-0391169-A2 | Enantiomeric pure 7-(3-amino-1-pyrrolidinyl)-chinolon-and-naphthyridon carboxylic acids | BAYER AG (DE) | 1990-10-10 | — | — | EP | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4665458-A1 | INHIBITING ALPHA V BETA8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| EP-0331960-A2 | Process for the preparation of enantiomerically homogeneous aminopyrrolidinyl naphthyridine and quinolone carboxylic acids | ABBOTT LABORATORIES (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4859776-A | (S)-7-(3-aminopyrrolidin-1-yl)-1-(ortho, para-difluorophenyl)-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid and method for its preparation | ABBOTT LABORATORIES (US) | 1989-08-22 | — | — | US | disclosed |
| US-4851418-A | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0304087-A2 | Quinolone and naphthyridine antibacterial agents containing an alpha-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | ACHE 2842/4885BCHE 1083/4885BACE1 724/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | ACHE 3656/4885BCHE 3812/4885BACE1 1001/4885 |
| US-20060281733-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, CNR1 | ACHE 3424/4885BCHE 1045/4885BACE1 1314/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | ACHE 4657/4885BCHE 3561/4885BACE1 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.